Peel Hunt reaffirmed their buy rating on shares of PureTech Health (LON:PRTC) in a research note published on Tuesday morning, ThisIsMoney.Co.Uk reports.
Separately, Liberum Capital reiterated a buy rating on shares of PureTech Health in a research note on Thursday, April 23rd.
Shares of LON PRTC opened at GBX 252 ($3.31) on Tuesday. The company has a current ratio of 1.21, a quick ratio of 1.18 and a debt-to-equity ratio of 6.04. PureTech Health has a 12 month low of GBX 2.11 ($0.03) and a 12 month high of GBX 339.36 ($4.46). The firm has a market capitalization of $726.24 million and a PE ratio of 1.76. The firm has a fifty day simple moving average of GBX 249.68 and a two-hundred day simple moving average of GBX 271.05.
About PureTech Health
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Recommended Story: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.